PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-08-09 pm EDT
49.78 USD   +0.42%
07:08aUNIVERSITY OF BRISTOL : Increase in non-COVID-19 respiratory infections predicted this winter
AQ
04:24aViiV Healthcare Announces Support for Community-Based Organizations With New Monkeypox Emergency Response Fund in the US
AQ
01:21aPfizer spending spree filters to Biopharma
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PFIZER INC : JP Morgan sticks Neutral

06/28/2022 | 08:08am EDT

In a research note, JP Morgan analyst Chris Schott has maintained his recommendation on the stock with a Neutral rating. The target price is unchanged and still at USD 57.


© MarketScreener with dpa-AFX Analyser 2022
All news about PFIZER, INC.
07:08aUNIVERSITY OF BRISTOL : Increase in non-COVID-19 respiratory infections predicted this win..
AQ
04:24aViiV Healthcare Announces Support for Community-Based Organizations With New Monkeypox ..
AQ
01:21aPfizer spending spree filters to Biopharma
AQ
01:12aPfizer Managing Director Tenders Resignation
MT
08/09Novavax tumbles 30% as waning COVID-19 vaccine demand hits outlook
RE
08/09Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Ta..
MT
08/09MARKETSCREENER’S WORLD PRESS REVIEW : August 9, 2022
MS
08/09Novavax tumbles 31% as waning COVID vaccine demand hits revenue forecast
RE
08/09EU Health Agency Starts Real-time Review of Pfizer-BioNTech's Variant-specific COVID-19..
MT
08/09EU regulator begins review of Pfizer-BioNTech's variant-adapted COVID shot
RE
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,83x
Yield 2022 3,25%
Capitalization 279 B 279 B -
EV / Sales 2022 2,63x
EV / Sales 2023 3,34x
Nbr of Employees 79 000
Free-Float 58,9%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 49,78 $
Average target price 56,53 $
Spread / Average Target 13,6%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-16.05%279 310
JOHNSON & JOHNSON-0.52%447 434
ELI LILLY AND COMPANY9.70%287 922
ROCHE HOLDING AG-16.02%275 991
ABBVIE INC.3.58%247 976
NOVO NORDISK A/S4.27%238 658